A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

Launched by BRISTOL-MYERS SQUIBB · Sep 26, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called BMS-986507, which is being tested in combination with other drugs for adults who have advanced solid tumors, like lung cancer. The main goals of the study are to find out if the treatment is safe, how well it is tolerated, and to see if it might work to help shrink the tumors. The trial is currently recruiting participants, and it is open to both men and women between the ages of 65 and 74.

To be eligible for the trial, participants should have at least one measurable tumor and a good level of physical ability, meaning they can carry out daily activities with little to no assistance. They should also expect to live for at least three more months at the time they start the study. However, people with a specific type of lung cancer that is a mix of small cell and non-small cell, or those with untreated brain metastases, serious infections, or severe heart conditions, cannot participate. If you or a loved one is considering joining this trial, it’s a good opportunity to contribute to research that may help improve treatment options for lung cancer.

Gender

ALL

Eligibility criteria

• • Inclusion Criteria
• • Participants must have at least one measurable lesion per response evaluation criteria in solid tumors.
• • Participants must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
• • Participants must have a life expectancy of at least 3 months at the time of the first dose.
• • Exclusion Criteria
• • Participants must not have any mixed Small Cell Lung Cancer (SCLC) and Non-Small Cell Lung Cancer (NSCLC) histology.
• • Participants must not have spinal cord compression, symptomatic central nervous system (CNS) metastases. Progression of existing CNS metastases, or the appearance of new lesions as shown on CNS imaging during screening will be excluded. Participants with CNS metastases discovered during screening may be eligible.
• • Participants must not have a history of serious recurrent infections.
• • Participants must not have a history of severe heart disease.
• • Other protocol-defined Inclusion/Exclusion criteria apply.